BridgeBio Pharma, Inc. (BBIO) company profile
Close on Nov 13, 2026Market cap $15.25BP/E –Yield –
About BridgeBio Pharma
Pharmaceutical Preparations, SIC 2834
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering treatments for patients with genetic diseases and significant unmet medical needs. Operating through a decentralized hub-and-spoke model, the company organizes program-specific development units supported by centralized operational and regulatory infrastructure. Its primary commercial product is acoramidis, a small molecule transthyretin stabilizer branded as Attruby in the United States and Beyonttra internationally for transthyretin amyloid cardiomyopathy. The enterprise also holds approved therapies such as Nulibry and advances late-stage clinical programs including infigratinib for skeletal conditions and encaleret for calcium regulation disorders. Its offerings serve patient populations diagnosed with rare genetic conditions through specialized medical treatment centers and healthcare practitioners.
The company distributes its lead treatment in the United States directly through a specialized network of specialty distributors, pharmacies, and approved hospital systems. Internationally, commercial activities reach patients through strategic collaboration partners, including Bayer across European territories and Alexion in Japan, alongside direct commercialization in selected markets. BridgeBio conducts business operations across the United States, Europe, and Asia, relying entirely on third-party contract organizations for product manufacturing.
Summary of the business section of BridgeBio Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BridgeBio Pharma, Inc.
- Founded
- 2015
- Headquarters
- Palo Alto, CA
- Address
- 3160 Porter Dr., Suite 250 94304
- Phone
- (650) 391-9740
- Website
- attruby.com
- Employees
- 834, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- BBIO
- Exchange
- Nasdaq
- IPO date
- Jun 28, 2019
- Shares outstanding
- 195M, Oct 22, 2026
- Public float
- $7.30B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1743881
- CUSIP
- 10806X102
- ISIN
- US10806X1028
- FIGI
- BBG00P9KDZK6
- Share class FIGI
- BBG00P9KDZL5
- LEI
- 54930028YG89VTY2J114
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Neil Kumar | Chief Executive Officer, Director | 5,058,739 |
| Maricel Apuli | Chief Accounting Officer | 120,687 |
| Thomas Trimarchi | President and CFO | 336,529 |
| Brian C. Stephenson | CFO and Treasurer | 110,964 |
| Andrea Ellis | Director | 39,746 |
| Jennifer E. Cook | Director | 8,383 |
| Ronald J. Daniels | Director | 20,981 |
| Andrew Lo | Director | 68,662 |
| Charles J. Homcy | Director | 919,876 |
| Fred Hassan | Director | 29,879 |
| Frank McCormick | Director | 767,244 |
| James C. Momtazee | Director | 99,070 |
| Eric Aguiar | Director | 10,579 |
| Hannah Valantine | Director | 9,657 |
| Douglas A. Dachille | Director | 30,579 |
| Ali J. Satvat | Director | 169,983 |
| Randal W. Scott | Director | 19,389 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $14.94M | $75.35M | $3.26M | $108 | $125 |
| FY2024 | $15.58M | -$2.66M | $6.08M | $39 | $93 |
| FY2023 | $12.16M | $70.06M | $6.65M | $57 | $94 |
| FY2022 | $6.67M | -$11.34M | $2.96M | $11 | $90 |
| FY2021 | $25.63M | -$132.75M | $8.68M | $23 | $100 |
| FY2020 | $10.05M | $151.06M | $4.76M | $203 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Neil Kumar Chief Executive Officer | $1.04M | $1.40M | $10.61M | $1.87M | $15.32K | $14.94M | -4% |
| Thomas Trimarchi President and Chief Financial Officer | $675.59K | $525.00K | $4.60M | – | $29.29K | $5.83M | -10% |
| Brian Stephenson Former Chief Financial Officer | $156.43K | – | – | – | $528.23K | $684.66K | -88% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 28, 2019
- Offer price
- $17.00
- Securities offered
- 20,500,000
- Gross proceeds
- $348.50M
- Exchange
- Nasdaq
- First trading day
- Jun 27, 2019
- First-day close
- $27.55+62.1%
- Lock-up ends (est.)
- Dec 24, 2019
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 834 full-time employees and 5 part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 26, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 15, 2020 | Merger vote | Definitive merger proxy statement |
| Nov 6, 2020 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 28, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 26, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 16, 2019 | Name change | Name changed from BridgeBio Pharma LLC to BridgeBio Pharma, Inc. |
See a number that looks wrong?